Ankle implant tracked for Long-Term success in arthritis patients
NCT ID NCT03247023
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 65 adults with ankle arthritis (from wear-and-tear, injury, or conditions like rheumatoid arthritis) who received the Cadence Total Ankle System implant. Researchers tracked how long the implant lasted without needing removal or revision, checking at 2, 5, and 10 years. The goal was to see if the device is safe and durable for long-term use.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Integra Cadence Total Ankle System (ankle replacement implant)
- What this could lead to
- If successful, this could confirm that the Cadence ankle implant is a safe and durable option for people with severe ankle arthritis, potentially improving mobility and reducing pain for years.
- What could go wrong
- This trial was terminated early and only enrolled 65 people, so results may be limited. As with any joint replacement, risks include implant loosening, infection, or need for revision surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
65 people
The number who actually took part.
- Started
-
Sep 2017
- Finished
-
Sep 2023
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with ankle arthritis requiring total ankle replacement
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Subjects will be included if he/she: 1. Is \> 18 years of age. 2. Is skeletally mature. 3. Qualifies for primary TAR per the surgeon and has a diagnosis of one of the following: primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), or systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis). 4. Is suitable for TAR with CTAS per the study surgeon based on the product indication and having considered deformity, stability, bone quality, soft- tissue envelope, and neurovascular status. 5. Is willing and able to cooperate in the required post-operative therapy. 6. Is willing and able to complete scheduled follow-up visits, evaluations, and questionnaires as described in the Informed Consent or Information Letter and Data Transfer Authorization Form, as applicable. 7. Reads, understands and signs the Ethical Committee approved Informed Consent or Information Letter and Data Transfer Authorization Form, as applicable Exclusion Criteria: Subjects will be excluded from the study if he/she: 1. Is Morbidly Obese (defined by BMI \> 40 or BMI of 35 - 40 with significant medical problems caused by or made worse by their weight). 2. Is an active nicotine user (smoking, chewing, smokeless tobacco, patch) and unwilling to cease nicotine use within 1 month prior to surgery, and 2 months post-surgery. 3. Has one of the following conditions, which could compromise the affected limb: ankle arthrodesis with malleolar exeresis, severe neurological (Charcot's Arthropathy) or vascular disease, loss of musculature or neuromuscular compromise. 4. Has an active local/systemic infection that may affect the prosthetic joint or has a recent history of infection. 5. Continues on long-term medication, which may compromise bone stock (e.g. undergoing immunosuppressive therapy, long-term steroids) and is unable to cease medication usage from 3 weeks prior to surgery to 3 weeks post-surgery. 6. Has a condition that may impair proper wound healing (e.g., poor soft tissue envelope). 7. Had previous ankle surgery and/or injury that has adversely affected the anklebone stock. 8. Has had or is scheduled to have contralateral TAR surgery. 9. Is pregnant or plans to become pregnant during the follow up period. 10. Has a metabolic disorder or disease that may compromise bone quality (e.g. arthrogryposis etc.), physiological or anatomical anomalies, and/or malignancy/local bone tumors. 11. Has severe avascular necrosis of the talus/tibia. 12. Has inadequate neuromuscular status (e.g., prior paralysis, severe neuropathy). 13. Has a known sensitivity or allergic reaction to one or more of the implanted materials. 14. Is a poor candidate for general anesthesia. 15. Is a prisoner, mentally incompetent or unable to understand what participation in this study entails, a known alcohol or drug abuser, or anticipated to be non- compliant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Degenerative arthritis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU Tours
Tours, 37044, France
-
Clinica Nostra Senhora del Remei
Barcelona, 08024, Spain
-
Foot and Ankle Institute
Woluwe-St-Lambert, B-1200, Belgium
-
North Cumbria University Hospitals
Carlisle, CA2 7HY, United Kingdom
-
St. Michael's Hospital
Toronto, M5C 1R6, Canada
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe why rheumatic pain feels different for everyone
- A new ankle? researchers track 400 people with an implant meant to restore movement
- Can a Job-Focused rehab program keep arthritis patients employed?
- Do rheumatic diseases quietly damage the Eye's oil glands?
- Hidden kidney damage may lurk in rheumatoid arthritis patients
- Can a new injection calm rheumatoid arthritis? an early trial puts ZB002 to the test